Analysts Offer Predictions for PROF Q1 Earnings

Profound Medical Corp. (NASDAQ:PROF) – Equities research analysts at Raymond James issued their Q1 2026 earnings estimates for shares of Profound Medical in a report issued on Tuesday, February 18th. Raymond James analyst M. Freeman forecasts that the company will post earnings of ($0.24) per share for the quarter. Raymond James currently has a “Strong-Buy” rating on the stock. The consensus estimate for Profound Medical’s current full-year earnings is ($1.15) per share. Raymond James also issued estimates for Profound Medical’s Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.19) EPS and Q4 2026 earnings at ($0.14) EPS.

Profound Medical Price Performance

NASDAQ PROF opened at $6.79 on Wednesday. Profound Medical has a one year low of $5.63 and a one year high of $11.42. The company has a 50-day simple moving average of $7.02 and a 200-day simple moving average of $7.76. The company has a quick ratio of 5.16, a current ratio of 6.12 and a debt-to-equity ratio of 0.11.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of PROF. Raymond James Financial Inc. acquired a new position in shares of Profound Medical in the 4th quarter valued at about $6,577,000. Magnetar Financial LLC bought a new stake in Profound Medical in the 4th quarter valued at about $3,826,000. MMCAP International Inc. SPC bought a new stake in Profound Medical in the 4th quarter valued at about $3,680,000. Altium Capital Management LLC bought a new stake in Profound Medical in the 4th quarter valued at about $3,642,000. Finally, Ring Mountain Capital LLC bought a new stake in Profound Medical in the 4th quarter valued at about $2,087,000. 47.86% of the stock is owned by institutional investors and hedge funds.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.